Form 4: Nuvalent Chief Scientific Officer Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, executed a pre-arranged Rule 10b5-1 trading plan on June 6, 2025, exercising stock options and subsequently selling 200 shares of Class A Common Stock.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), engaged in transactions involving the company's Class A Common Stock on June 6, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan, which was adopted on November 1, 2024.
• Mr. Pelish exercised stock options to acquire 100 shares at an exercise price of $27.85 and another 100 shares at an exercise price of $29.33.
• Concurrently, he sold 200 shares of Class A Common Stock at a price of $79.82 per share.
• Following these transactions, Mr. Pelish's direct beneficial ownership of Class A Common Stock stands at 63,101 shares.
• The exercised options were part of grants that vest over four years in equal monthly installments, starting from January 6, 2023, and March 1, 2023, respectively, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about its signaling effect. The officer also realized a significant profit from the option exercises, which is a positive for the individual and reflects the company's stock performance.

Positives

• The exercise of stock options indicates the officer is realizing value from their compensation, which is a normal part of executive compensation.
• The sale price of $79.82 is significantly higher than the exercise prices of $27.85 and $29.33, indicating a substantial profit for the officer on the exercised shares.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale was not based on new, non-public information.

Negatives

• The sale of shares by a Chief Scientific Officer, even under a 10b5-1 plan, represents a reduction in direct insider ownership.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Henry E. Pelish, Chief Scientific Officer, exercised stock options and sold shares of Nuvalent, Inc. Class A Common Stock, which constitutes a related party transaction as an insider dealing.

Stakeholder Impact

• Shareholders may view the sale of shares by a Chief Scientific Officer with slight caution, although the pre-arranged nature of the Rule 10b5-1 plan generally mitigates concerns about its implications for the company's future prospects.

Key Dates

Keywords

Nuvalent Inc., NUVL, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Chief Scientific Officer, Henry E. Pelish, Equity Transaction, Beneficial Ownership